GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xbrane Biopharma AB (OSTO:XBRANE) » Definitions » Median PS Value

Xbrane Biopharma AB (OSTO:XBRANE) Median PS Value : kr0.00 (As of Jun. 06, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Xbrane Biopharma AB Median PS Value?

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Xbrane Biopharma AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was kr0.731. Xbrane Biopharma AB's 10-Year median PS Ratio is 0. Therefore, the Median PS Value for today is kr0.00.

As of today (2024-06-06), Xbrane Biopharma AB's share price is kr0.323. Xbrane Biopharma AB's Median PS Value is kr0.00. Therefore, Xbrane Biopharma AB's Price to Median PS Value for today is 0.00.

The historical rank and industry rank for Xbrane Biopharma AB's Median PS Value or its related term are showing as below:

OSTO:XBRANE's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.68
* Ranked among companies with meaningful Price-to-Median-PS-Value only.

Xbrane Biopharma AB Median PS Value Historical Data

The historical data trend for Xbrane Biopharma AB's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xbrane Biopharma AB Median PS Value Chart

Xbrane Biopharma AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Median PS Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Xbrane Biopharma AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Median PS Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Xbrane Biopharma AB's Median PS Value

For the Biotechnology subindustry, Xbrane Biopharma AB's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xbrane Biopharma AB's Price-to-Median-PS-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xbrane Biopharma AB's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where Xbrane Biopharma AB's Price-to-Median-PS-Value falls into.



Xbrane Biopharma AB Median PS Value Calculation

Xbrane Biopharma AB's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=0.731*0
=0.00

10-Year Median PS Ratio is 0.
Xbrane Biopharma AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.731.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Xbrane Biopharma AB  (OSTO:XBRANE) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

Xbrane Biopharma AB's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=0.323/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Xbrane Biopharma AB Median PS Value Related Terms

Thank you for viewing the detailed overview of Xbrane Biopharma AB's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Xbrane Biopharma AB (OSTO:XBRANE) Business Description

Traded in Other Exchanges
Address
Retzius vag 8, Solna, SWE, 171 65
Xbrane Biopharma AB is a biotechnology company that develops biosimilars. The company has a patented protein production platform with up to 12 times greater productivity than standard systems for the production of proteins in E.coli host cells. Xbrane's leading product candidate is Ximluci, a ranibizumab biosimilar (original drug Lucentis) used in the treatment of various eye diseases, mainly the wet form of age-related macular degeneration. The company's geographical segments include the Middle East, Asia, Europe, and the United States.

Xbrane Biopharma AB (OSTO:XBRANE) Headlines

No Headlines